Published in Cancer Chemother Pharmacol on January 01, 1987
Eliminating encephalitogenic T cells without undermining protective immunity. J Immunol (2013) 0.79
Topoisomerase expression in cancer cell lines and clinical samples. Cancer Chemother Pharmacol (1994) 0.78
Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. J Biol Chem (1987) 1.66
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol (2004) 1.51
Inhibition of p34cdc2 kinase activity by etoposide or irradiation as a mechanism of G2 arrest in Chinese hamster ovary cells. Cancer Res (1990) 1.49
Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst (1999) 1.47
Assembly and transcription of synthetic vesicular stomatitis virus nucleocapsids. J Virol (1991) 1.47
Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer. Int J Radiat Oncol Biol Phys (1995) 1.40
The role of adjuvant surgery in the combined modality therapy of small-cell bronchogenic carcinoma after a chemotherapy-induced partial remission. J Clin Oncol (1990) 1.40
Proliferation dependence of topoisomerase II mediated drug action. Biochemistry (1986) 1.37
Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res (2001) 1.37
DNA double-stranded breaks in mammalian cells after exposure to intercalating agents. Biochim Biophys Acta (1981) 1.34
Qualitative and quantitative aspects of intercalator-induced DNA strand breaks. Biochim Biophys Acta (1979) 1.34
Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol (2001) 1.33
Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol (2000) 1.16
DNA topoisomerases as targets for cancer therapy. Biochem Pharmacol (1985) 1.15
DNA damage as a basis for 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) (etoposide) cytotoxicity. Cancer Res (1983) 1.14
Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res (1988) 1.13
Characterization of acquired epipodophyllotoxin resistance in a Chinese hamster ovary cell line: loss of drug-stimulated DNA cleavage activity. Cancer Res (1986) 1.13
Protein-associated DNA breaks in cells treated with adriamycin or ellipticine. Biochim Biophys Acta (1978) 1.13
Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol (1998) 1.11
Kinetics of formation and disappearance of a DNA cross-linking effect in mouse leukemia L1210 cells treated with cis- and trans-diamminedichloroplatinum(II). Cancer Res (1978) 1.11
Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol (1996) 1.10
Topoisomerase-specific drug sensitivity in relation to cell cycle progression. Mol Cell Biol (1987) 1.09
UP element-dependent transcription at the Escherichia coli rrnB P1 promoter: positional requirements and role of the RNA polymerase alpha subunit linker. Nucleic Acids Res (2001) 1.08
Differences between melphalan and nitrogen mustard in the formation and removal of DNA cross-links. Cancer Res (1978) 1.04
A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer (2001) 1.02
Purification and characterization of an altered topoisomerase II from a drug-resistant Chinese hamster ovary cell line. Biochemistry (1989) 1.02
Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol (1996) 1.01
DNA binding by epipodophyllotoxins and N-acyl anthracyclines: implications for mechanism of topoisomerase II inhibition. Mol Pharmacol (1988) 0.99
Possible role for p34cdc2 kinase in etoposide-induced cell death of Chinese hamster ovary cells. Cancer Res (1990) 0.98
Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study. Cancer (1983) 0.97
Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions. Semin Oncol (2000) 0.97
DNA topoisomerase II: a primer on the enzyme and its unique role as a multidrug target in cancer chemotherapy. Pharmacol Ther (1987) 0.95
Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells. Cancer Res (1987) 0.95
Potentiation of etoposide-induced DNA damage by calcium antagonists in L1210 cells in vitro. Cancer Res (1984) 0.94
Comparison of microsomal drug hydroxylation in lung and liver of various species. Res Commun Chem Pathol Pharmacol (1970) 0.94
Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement. Semin Oncol (1998) 0.94
Verapamil-induced augmentation of etoposide accumulation in L1210 cells in vitro. Cancer Res (1985) 0.91
A pilot investigation of the psychologic functioning of patients with anticipatory vomiting. Cancer (1982) 0.88
Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol (2001) 0.88
Depletion of topoisomerase II in isolated nuclei during a glucose-regulated stress response. Mol Cell Biol (1989) 0.88
Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer (2001) 0.87
Enhanced expression of HLA-A,B,C and inducibility of TAP-1, TAP-2, and HLA-A,B,C by interferon-gamma in a multidrug-resistant small cell lung cancer line. Lymphokine Cytokine Res (1994) 0.87
Potentiation of bleomycin toxicity by oxygen. Cancer Treat Rep (1982) 0.87
Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer (2001) 0.85
Primary chemotherapy of brain metastasis in small-cell lung cancer. J Clin Oncol (1989) 0.85
DNA topoisomerases in cancer therapy. Anticancer Drug Des (1987) 0.85
Characterization of VP-16-induced DNA damage in isolated nuclei from L1210 cells. Biochim Biophys Acta (1984) 0.85
Effects of verapamil on etoposide, vincristine, and adriamycin activity in normal human bone marrow granulocyte-macrophage progenitors and in human K562 leukemia cells in vitro. Cancer Res (1985) 0.84
Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma: results of a matched cohort study. Cancer (1997) 0.84
A pilot trial of hyperfractionated thoracic radiation therapy with concurrent cisplatin and oral etoposide for locally advanced inoperable non-small-cell lung cancer: a 5-year follow-up report. Int J Radiat Oncol Biol Phys (1998) 0.83
Improved therapeutic index by leucovorin of edatrexate, cyclophosphamide, and cisplatin regimen for non-small-cell lung cancer. J Natl Cancer Inst (1992) 0.82
Repair of deoxyribonucleic acid lesions caused by adriamycin and ellipticine. Biochem Pharmacol (1982) 0.82
Relationship between cytotoxicity and DNA strand breakage produced by adriamycin and other intercalating agents. Int J Radiat Oncol Biol Phys (1979) 0.82
A method for assessing damage to mitochondrial DNA caused by radiation and epichlorohydrin. Mol Pharmacol (1985) 0.82
Inhibition of topoisomerases by fredericamycin A. Cancer Chemother Pharmacol (1989) 0.81
Paraquat-induced DNA damage in mammalian cells. Biochem Biophys Res Commun (1979) 0.81
Glycogen-containing neuroblastoma with clinical and histopathologic features of Ewing's sarcoma. Cancer (1978) 0.81
Paclitaxel/carboplatin chemotherapy as primary treatment of brain metastases in non-small cell lung cancer: a preliminary report. Semin Oncol (1997) 0.81
Survival after treatment of small-cell lung cancer: an endless uphill battle. J Natl Cancer Inst (1997) 0.81
Resectability of small-cell lung cancer following induction chemotherapy in patients with limited disease (stage II-IIIb). Am J Clin Oncol (1991) 0.80
Dissociation of cytotoxicity and DNA cleavage activity induced by topoisomerase II-reactive intercalating agents in hamster-human somatic cell hybrids. Cancer Chemother Pharmacol (1992) 0.80
Unconventional cancer therapy. Compr Ther (1985) 0.79
Abrogation of etoposide-mediated cytotoxicity by cycloheximide. Biochem Pharmacol (1988) 0.79
Role of proliferation in determining sensitivity to topoisomerase II-active chemotherapy agents. NCI Monogr (1987) 0.79
Inhibition of etoposide-induced DNA damage and cytotoxicity in L1210 cells by dehydrogenase inhibitors and other agents. Cancer Res (1984) 0.79
Altered function of DNA topoisomerases as a basis for antineoplastic drug action. Important Adv Oncol (1988) 0.79
Mediation of multi-drug resistance in a Chinese hamster ovary cell line by a mutant type II topoisomerase. NCI Monogr (1987) 0.78
Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53). Cancer Gene Ther (2000) 0.78
Relationship between DNA damage and survival in formaldehyde-treated mouse cells. Mutat Res (1980) 0.78
Phase I/II trial of radiation with chemotherapy "boost" for advanced squamous cell carcinomas of the head and neck: toxicities and responses. J Clin Oncol (1999) 0.78
Sex-dependent effects of cyclic AMP on the hepatic mixed function oxidase system. Res Commun Chem Pathol Pharmacol (1973) 0.77
Retinoic acid and interferon combination studies in human cancer. Eur J Cancer (1993) 0.77
Phase II study of intravenous Doxil in malignant pleural mesothelioma. Invest New Drugs (2000) 0.77
Phase II study of tiazofurin (NSC 286193) in the treatment of advanced small cell bronchogenic carcinoma. Invest New Drugs (1988) 0.76
Isolation and purification of large quantities of DNA replication intermediates by pH step alkaline elution. Chromosoma (1979) 0.76
Does induction chemotherapy have a role in the management of nasopharyngeal carcinoma? Results of treatment in the era of computerized tomography. Int J Radiat Oncol Biol Phys (1996) 0.76
Primary chemotherapy of advanced head and neck cancer: where do we go from here? J Natl Cancer Inst (1996) 0.75
Comparison of DNA damage by methylmelamines and formaldehyde. J Natl Cancer Inst (1981) 0.75
The CVOS Group M and N reports. Ophthalmology (1996) 0.75
Influence of astigmatism on multifocal and monofocal intraocular lenses. Am J Ophthalmol (2001) 0.75
Cytotoxicity and deoxyribonucleic acid damage associated with bromoacetate. Biochem Pharmacol (1981) 0.75
Beyond kinetics: the study of DNA damage and repair in bone marrow cells. Exp Hematol (1979) 0.75
Probenecid inhibition of methotrexate cytotoxicity in mouse L1210 leukemia cells. Cancer Treat Rep (1984) 0.75
Properties of a purified nuclear topoisomerase from L1210 cells. Biochim Biophys Acta (1983) 0.75
Ifosfamide with mesna uroprotection in the management of lung cancer. Am J Clin Oncol (1990) 0.75
Impact of managed care on one training program. University of Florida at Gainesville. Arch Surg (1995) 0.75
Edatrexate improves the antitumor effects of cyclophosphamide and cisplatin against non-small cell lung cancer. Cancer (1991) 0.75
Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck. Semin Oncol (1997) 0.75
Medical schools on the fault line. J Fla Med Assoc (1994) 0.75
Effect of retinoic acid on DNA cleavage and cytotoxicity of topoisomerase II-reactive drugs in a human head and neck squamous carcinoma cell line. Cancer Res (1989) 0.75
A study of drug-induced kinetic perturbations in the marrow of a patient with neuroblastoma. Cancer (1980) 0.75